Next Article in Journal
Fe3O4-Au Core-Shell Nanoparticles as a Multimodal Platform for In Vivo Imaging and Focused Photothermal Therapy
Next Article in Special Issue
Development and Bio-Predictive Evaluation of Biopharmaceutical Properties of Sustained-Release Tablets with a Novel GPR40 Agonist for a First-in-Human Clinical Trial
Previous Article in Journal
Anticonvulsant Action of GluN2A-Preferring Antagonist PEAQX in Developing Rats
Previous Article in Special Issue
Determination of Inherent Dissolution Performance of Drug Substances
 
 
Article

Article Versions Notes

Pharmaceutics 2021, 13(3), 417; https://doi.org/10.3390/pharmaceutics13030417
Action Date Notes Link
article pdf uploaded. 20 March 2021 07:43 CET Version of Record https://www.mdpi.com/1999-4923/13/3/417/pdf-vor
article supplementary file uploaded. 20 March 2021 07:43 CET - https://www.mdpi.com/1999-4923/13/3/417#supplementary
article xml file uploaded 22 March 2021 07:33 CET Original file -
article xml uploaded. 22 March 2021 07:33 CET Update https://www.mdpi.com/1999-4923/13/3/417/xml
article pdf uploaded. 22 March 2021 07:33 CET Updated version of record https://www.mdpi.com/1999-4923/13/3/417/pdf
article html file updated 22 March 2021 07:34 CET Original file -
article html file updated 25 March 2021 20:49 CET Update -
article html file updated 25 July 2022 08:29 CEST Update https://www.mdpi.com/1999-4923/13/3/417/html
Back to TopTop